Doseology Launches Feed That Brain® Oral Stimulant Pouches in the U.S. Through Direct-to-Consumer Pilot
MWN-AI** Summary
Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) has officially launched its Feed That Brain® Energy Pouches in the U.S. as part of a direct-to-consumer pilot program. These nicotine-free, caffeine-based oral stimulant pouches aim to provide a clean and controlled energy boost in a discreet format. The product is now available for purchase on feedthatbrain.com and Amazon.com, marking a significant step for Doseology in establishing a scalable stimulant delivery platform.
The Feed That Brain pouches represent an innovative approach to energy supplementation, offering an alternative to traditional energy drinks with the benefits of portion control and without sugar, smoke, or liquid consumption. The pilot program is designed to assess consumer adoption patterns and repeated purchasing behaviors, particularly among demographics seeking healthier, portable energy alternatives.
Larry Latowsky, Executive Chairman of Doseology, emphasized the importance of this pilot in understanding consumer preferences and building a sustainable business model around oral stimulant products. As consumer habits shift toward convenient delivery systems, the company positions itself to capture a growing market segment in the oral pouch category, which has seen rapid expansion and acceptance.
In conjunction with the product launch, Doseology announced the granting of restricted share units (RSUs) and performance share units (PSUs) to members of the board, aligning executive compensation with the company’s long-term growth objectives. This strategic move reflects the company's commitment to fostering value for shareholders while navigating the evolving landscape of functional consumer products.
Overall, Doseology's entrance into the U.S. market with Feed That Brain pouches underscores a broader trend toward innovative, discreet health solutions amidst the growing demand for effective energy alternatives.
MWN-AI** Analysis
The launch of Doseology’s Feed That Brain® Energy Pouches represents a significant strategic move into the rapidly evolving oral pouch market, which is seeing increased consumer interest in discreet, portable alternatives to traditional energy products. By leveraging a direct-to-consumer model, Doseology (CSE: MOOD, OTCQB: DOSEF) is positioning itself to capture a significant share of a market that aligns with contemporary consumer preferences for convenience and health-conscious options.
Investors should consider the broader implications of this move. The success of this pilot program will hinge on how well Doseology can evaluate consumer adoption rates and the purchasing habits of its target demographic, particularly those moving away from traditional energy drinks. With the growing acceptance of oral pouch formats, partly influenced by the rise of the nicotine pouch market, Doseology is ideally situated to benefit from this trend—if it can build a loyal customer base.
Financial analysts should closely monitor sales data from feedthatbrain.com and Amazon.com to gauge consumer response. Strong sales may validate the oral pouch model, potentially paving the way for broader product offerings and market expansion. Additionally, the company has aligned its executive compensation with performance milestones, promoting a long-term focus on growth.
From a risk perspective, potential investors should be aware of the challenges that may arise, including intense competition and regulatory hurdles in the health and wellness sector. Therefore, while Doseology presents exciting growth opportunities within a dynamic market, careful scrutiny is warranted. Overall, this venture holds promise for both consumers seeking alternatives and investors looking for innovative growth strategies in an expanding niche.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
KELOWNA, BC, March 4, 2026 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) ("Doseology" or the "Company") today announced the launch of the Feed That Brain® Energy Pouches, marking the Company's first direct-to-consumer pilot program in the United States.
Feed That Brain Energy Pouches deliver clean, controlled energy in a discreet oral pouch format, powered by Doseology®. The nicotine-free, caffeine-based product is designed to provide predictable, portion-controlled stimulation without sugar, smoke, or liquid consumption. The pouches are now available exclusively to U.S. consumers at feedthatbrain.com and Amazon.com.
The U.S. pilot represents a key milestone in Doseology's strategy to validate oral pouch delivery as a scalable stimulant platform, beginning with non-nicotine energy products. The Company will use this phase to evaluate consumer adoption, usage frequency, and repeat purchase behaviour, with particular focus on underserved demographics seeking alternatives to traditional energy drinks.
"This U.S. pilot is a disciplined and deliberate step in Doseology's strategy to build a scalable oral stimulant platform," said Larry Latowsky, Executive Chairman of Doseology, "Feed That Brain demonstrates how controlled, non-nicotine energy delivery can meet evolving consumer preferences while generating the operational insight required for responsible growth."
Feed That Brain Energy Pouches are designed for modern, on-the-go use, offering consumers clarity and control without the volatility commonly associated with liquid energy formats. The product reflects Doseology's broader focus on precision dosing, predictability, and experience-led design.
The Company notes that increasing consumer adoption of oral pouch formats reflects a broader shift toward portable and discreet delivery systems. While Feed That Brain is nicotine-free, the rapid growth of the U.S. nicotine pouch category highlights rising acceptance of pouch-based delivery, supporting the long-term relevance of the format.
The Company also announced that it has granted 140,000 restricted share units ("RSUs") and 210,000 performance share units ("PSUs") to a director of the Company. The RSUs vest in equal monthly increments over 36 months from the date of grant. The PSUs vest upon achievement of defined performance milestones, aligning compensation with long-term value creation.
About Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70)
Doseology Sciences Inc. specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation.
From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation. The pouch sector represents one of the most dynamic and high-growth areas in modern functional consumer products.
For more information:
doseology.com / feedthatbrain.com
On behalf of the Board of Directors, Chris Jackson
CEO, Director
Doseology Sciences Inc.
Investor & Media Contact:
Email: hello@doseology.com
Phone: 604.908.3095
Forward Looking Statements
This press release contains statements that constitute "forward?looking information" within the meaning of applicable securities laws. Forward?looking information is often identified by the words "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect" or similar expressions. Readers are cautioned that forward?looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward?looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward?looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company's prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward?looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward?looking information except as otherwise required by applicable law. For more information, investors should review the Company's filings which are available on SEDAR+.
No securities regulatory authority has either approved or disapproved of the contents of this press release.
Logo - https://mma.prnewswire.com/media/2858641/5832014/Doseology_Sciences_Inc_Logo.jpg
SOURCE Doseology Sciences Inc.
FAQ**
What metrics will Doseology Sciences DOSEF use to evaluate consumer adoption and repeat purchase behavior during the U.S. pilot of Feed That Brain® Energy Pouches?
How does Doseology Sciences DOSEF plan to differentiate its Feed That Brain® Energy Pouches from traditional energy drinks and competing oral pouch products in the market?
Given the growth of the U.S. nicotine pouch category, what strategies does Doseology Sciences DOSEF have in place to capitalize on the rising acceptance of pouch formats among consumers?
What operational insights does Doseology Sciences DOSEF aim to gain during the U.S. pilot that may inform the future development of their oral stimulant products?
**MWN-AI FAQ is based on asking OpenAI questions about Doseology Sciences (OTC: DOSEF).
NASDAQ: DOSEF
DOSEF Trading
0.0% G/L:
$0.5475 Last:
500 Volume:
$0.5475 Open:
